Skip to main content

Research Repository

Advanced Search

Upregulation of Cyclin B2 (CCNB2) in breast cancer contributes to the development of lymphovascular invasion

Aljohani, Abrar I; Toss, Michael S; El-Sharawy, Khloud A; Mirza, Sameer; Ball, Graham R; Green, Andrew R; Rakha, Emad

Upregulation of Cyclin B2 (CCNB2) in breast cancer contributes to the development of lymphovascular invasion Thumbnail


Authors

Abrar I Aljohani

Michael S Toss

Khloud A El-Sharawy

Sameer Mirza

Graham R Ball

EMAD RAKHA Emad.Rakha@nottingham.ac.uk
Professor of Breast Cancer Pathology



Abstract

Lymphovascular invasion (LVI) is a key step in breast cancer (BC) metastasis. Targeting the molecular drivers of LVI can improve BC patients’ management. However, the underlying molecular mechanisms of LVI are complex and interconnected with various carcinogenesis pathways. This study aimed to identify the key regulatory gene associated with LVI and to investigate its mechanisms of action and prognostic significance. Artificial neural network (ANN) was applied to two large transcriptomic datasets of BC with well-characterised LVI status. Cyclin B2 (CCNB2) was identified in the top genes associated with LVI positivity. In vitro functional assays were carried out to assess the role of CCNB2 in tumour cell behaviour and their interactions with endothelial cells using a panel of BC cell lines. Large annotated BC cohorts were used to assess the clinical and prognostic role of CCNB2 at the transcriptomic and protein levels. Knockdown (KD) of CCNB2 mRNA reduced BC cell migration, inhibited proliferation, blocked the G2/M transition during the cell cycle and increased the number of apoptotic cells. Importantly, KD of CCNB2 reduced BC cell lines adherence and transmigration across endothelial cell lines. High CCNB2 protein expression was independently associated with LVI positivity in addition to other features of aggressive behaviour, including larger tumour size, higher histological grade, hormonal receptor-negativity, and HER2-positivity, and with shorter survival. We conclude that CCNB2 plays a crucial role in LVI development in BC, implying that CCNB2 could confer a promising therapeutic target to inhibit LVI and reduce metastatic events.

Citation

Aljohani, A. I., Toss, M. S., El-Sharawy, K. A., Mirza, S., Ball, G. R., Green, A. R., & Rakha, E. (2022). Upregulation of Cyclin B2 (CCNB2) in breast cancer contributes to the development of lymphovascular invasion. American Journal of Cancer Research, 12(2), 469-489

Journal Article Type Article
Acceptance Date Jan 10, 2022
Online Publication Date Feb 15, 2022
Publication Date Feb 15, 2022
Deposit Date Apr 7, 2022
Publicly Available Date Apr 7, 2022
Electronic ISSN 2156-6976
Peer Reviewed Peer Reviewed
Volume 12
Issue 2
Pages 469-489
Public URL https://nottingham-repository.worktribe.com/output/7711682
Publisher URL https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899993/
Related Public URLs https://e-century.us/web/journal_toc.php?journal=ajcr&volume=12&number=2

Files





You might also like



Downloadable Citations